SiRNA Targeting YAP Gene Inhibits Gastric Carcinoma Growth and Tumor Metastasis in SCID Mice

Overview

Journal Oncol Lett

Specialty Oncology

Date 2016 Apr 14

PMID 27073556

Citations 19

Authors

Zhou Zhou

Jin-Shui Zhu

Cai-Ping Gao

Liang-Ping Li

Chao Zhou

Han Wang

Xiao-Gang Liu

Affiliations

Soon will be listed here.

Abstract

Yes-associated protein (YAP) is constitutively activated in numerous types of cancer, including gastric carcinoma. The aim of the present study was to investigate the effects of YAP silencing on proliferation, apoptosis, metastasis and angiogenesis in a gastric orthotopic implantation cancer model of severe combined immunodeficiency mice. Small-hairpin RNA (shRNA) targeting the YAP gene was employed to inhibit YAP expression. SGC7901 cells transfected with YAP shRNA demonstrated significantly decreased gastric cancer growth and metastasis in the orthotopic implantation mouse model. Silencing of YAP additionally promoted tumor cell apoptosis, and inhibited tumor cell proliferation and angiogenesis. Notably, YAP shRNA also downregulated the expression of TEA domain family member 1, cyclinD1, vascular endothelial growth factor and fibroblast growth factor-2. The results of the present study suggested that YAP may have a significant role in the proliferation, metastasis and angiogenesis of gastric cancer. RNA interference-mediated silencing of YAP may provide an opportunity to develop a novel treatment strategy for gastric cancer.

Citing Articles

A literature review of recent advances in gastric cancer treatment: exploring the cross-talk between targeted therapies.

Panahizadeh R, Panahi P, Asghariazar V, Makaremi S, Noorkhajavi G, Safarzadeh E Cancer Cell Int. 2025; 25(1):23.

PMID: 39856676 PMC: 11762578. DOI: 10.1186/s12935-025-03655-8.

Plasminogen activator urokinase interacts with the fusion protein and antagonizes the growth of Peste des petits ruminants virus.

Wu J, Yang W, Li L, Wu J, He J, Ru Y J Virol. 2024; 98(4):e0014624.

PMID: 38440983 PMC: 11019896. DOI: 10.1128/jvi.00146-24.

Polyacetylene Isomers Isolated from L. Suppress the Metastasis of Gastric Cancer Cells by Inhibiting Wnt/-Catenin and Hippo/YAP Signaling Pathways.

Cai J, Shi S, Cheng F, Wei M, Zou K, Yu X Molecules. 2023; 28(4).

PMID: 36838824 PMC: 9962988. DOI: 10.3390/molecules28041837.

YAP/TAZ as master regulators in cancer: modulation, function and therapeutic approaches.

Piccolo S, Panciera T, Contessotto P, Cordenonsi M Nat Cancer. 2022; 4(1):9-26.

PMID: 36564601 PMC: 7614914. DOI: 10.1038/s43018-022-00473-z.

Combined Inhibition of FOSL-1 and YAP Using siRNA-Lipoplexes Reduces the Growth of Pancreatic Tumor.

Diego-Gonzalez L, Fernandez-Carrera A, Igea A, Martinez-Perez A, Real Oliveira M, Gomes A Cancers (Basel). 2022; 14(13).

PMID: 35804874 PMC: 9265026. DOI: 10.3390/cancers14133102.

References

Amoedo N, El-Bacha T, Rodrigues M, Rumjanek F . Cell cycle and energy metabolism in tumor cells: strategies for drug therapy. Recent Pat Anticancer Drug Discov. 2010; 6(1):15-25. DOI: 10.2174/157489211793980006. View

Cao R, Ji H, Feng N, Zhang Y, Yang X, Andersson P . Collaborative interplay between FGF-2 and VEGF-C promotes lymphangiogenesis and metastasis. Proc Natl Acad Sci U S A. 2012; 109(39):15894-9. PMC: 3465417. DOI: 10.1073/pnas.1208324109. View

Guo H, Guan P, Shi H, Zhang X, Zhou B, Yuan Y . Prospective cohort study of comprehensive prevention to gastric cancer. World J Gastroenterol. 2003; 9(3):432-6. PMC: 4621555. DOI: 10.3748/wjg.v9.i3.432. View

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

Moroishi T, Hansen C, Guan K . The emerging roles of YAP and TAZ in cancer. Nat Rev Cancer. 2015; 15(2):73-79. PMC: 4562315. DOI: 10.1038/nrc3876. View

Singh S, Sadanandam A, Singh R . Chemokines in tumor angiogenesis and metastasis. Cancer Metastasis Rev. 2007; 26(3-4):453-67. PMC: 4237067. DOI: 10.1007/s10555-007-9068-9. View

Liu-Chittenden Y, Huang B, Shim J, Chen Q, Lee S, Anders R . Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev. 2012; 26(12):1300-5. PMC: 3387657. DOI: 10.1101/gad.192856.112. View

Thalheimer A, Otto C, Bueter M, Illert B, Gattenlohner S, Gasser M . Tumor cell dissemination in a human colon cancer animal model: orthotopic implantation or intraportal injection?. Eur Surg Res. 2009; 42(3):195-200. DOI: 10.1159/000205825. View

Barzi A, Thara E . Angiogenesis in esophageal and gastric cancer: a paradigm shift in treatment. Expert Opin Biol Ther. 2014; 14(9):1319-32. DOI: 10.1517/14712598.2014.921677. View

10.

Lamar J, Stern P, Liu H, Schindler J, Jiang Z, Hynes R . The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. Proc Natl Acad Sci U S A. 2012; 109(37):E2441-50. PMC: 3443162. DOI: 10.1073/pnas.1212021109. View

11.

Zhou Z, Zhu J, Xu Z . RNA interference mediated YAP gene silencing inhibits invasion and metastasis of human gastric cancer cell line SGC-7901. Hepatogastroenterology. 2011; 58(112):2156-61. DOI: 10.5754/hge11234. View

12.

Zhou Z, Zhu J, Xu Z, Zhang Q . Lentiviral vector-mediated siRNA knockdown of the YAP gene inhibits growth and induces apoptosis in the SGC7901 gastric cancer cell line. Mol Med Rep. 2011; 4(6):1075-82. DOI: 10.3892/mmr.2011.543. View

13.

Hong W, Guan K . The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian Hippo pathway. Semin Cell Dev Biol. 2012; 23(7):785-93. PMC: 3459069. DOI: 10.1016/j.semcdb.2012.05.004. View

14.

Mizuno T, Murakami H, Fujii M, Ishiguro F, Tanaka I, Kondo Y . YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes. Oncogene. 2012; 31(49):5117-22. DOI: 10.1038/onc.2012.5. View

15.

Tuettenberg J, Friedel C, Vajkoczy P . Angiogenesis in malignant glioma--a target for antitumor therapy?. Crit Rev Oncol Hematol. 2006; 59(3):181-93. DOI: 10.1016/j.critrevonc.2006.01.004. View

16.

Umekita Y, Ohi Y, Sagara Y, Yoshida H . Overexpression of cyclinD1 predicts for poor prognosis in estrogen receptor-negative breast cancer patients. Int J Cancer. 2002; 98(3):415-8. DOI: 10.1002/ijc.10151. View

17.

Lehnert T, Rudek B, Buhl K, Golling M . Surgical therapy for loco-regional recurrence and distant metastasis of gastric cancer. Eur J Surg Oncol. 2002; 28(4):455-61. DOI: 10.1053/ejso.2002.1260. View

18.

Pestell R . New roles of cyclin D1. Am J Pathol. 2013; 183(1):3-9. PMC: 3702737. DOI: 10.1016/j.ajpath.2013.03.001. View

19.

Duchrow M, Schluter C, Key G, Kubbutat M, Wohlenberg C, Flad H . Cell proliferation-associated nuclear antigen defined by antibody Ki-67: a new kind of cell cycle-maintaining proteins. Arch Immunol Ther Exp (Warsz). 1995; 43(2):117-21. View

20.

Felley-Bosco E, Stahel R . Hippo/YAP pathway for targeted therapy. Transl Lung Cancer Res. 2015; 3(2):75-83. PMC: 4367659. DOI: 10.3978/j.issn.2218-6751.2014.02.03. View